BMT CTN Protocol 1302

Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma.

Below are protocol-related documents, which may be periodically updated.

            Protocol Co-Chair: Parameswaran Hari, MD phari@mcw.edu

            Protocol Co-Chair: Taiga Nishihori, MD taiga.nishihori@moffitt.org

            Protocol Co-Chair: Qaiser Bashir, MD (713-794-4422) qbashir@mdanderson.org

            Protocol Officer: Marcelo Pasquini, MD mpasquini@mcw.edu

            Protocol Coordinator: Sam Wilkins (301-251-1161) swilkins@emmes.com

            Medical Monitor: Dianna Howard, MD dshowa0@email.uky.edu

The BMT CTN is committed to including widespread transplant community participation in these trials. However, affiliate center applications are not currently being accepted for this study. The protocol closed to enrollment on September 14, 2018.